7 results on '"Maria, Markoulli"'
Search Results
2. Chronic Kidney Disease Has No Impact on Tear Film Substance P Concentration in Type 2 Diabetes
- Author
-
Kofi Asiedu, Sultan Alotaibi, Arun V. Krishnan, Natalie Kwai, Ann Poynten, Maria Markoulli, and Roshan Dhanapalaratnam
- Subjects
diabetic neuropathy ,peripheral neuropathy ,substance p ,chronic kidney disease ,cornea ,Biology (General) ,QH301-705.5 - Abstract
Purpose: The study aimed to ascertain the potential effects of chronic kidney disease (CKD) on substance P concentration in the tear film of people with type 2 diabetes. Methods: Participants were classified into two groups: type 2 diabetes with concurrent chronic kidney disease (T2DM–CKD (n = 25)) and type 2 diabetes without chronic kidney disease (T2DM–no CKD (n = 25)). Ocular surface discomfort assessment, flush tear collection, in-vivo corneal confocal microscopy, and peripheral neuropathy assessment were conducted. Enzyme-linked immunosorbent assays were utilized to ascertain the levels of tear film substance P in collected flush tears. Correlation analysis, hierarchical multiple linear regression analysis, and t-tests or Mann–Whitney U tests were used in the analysis of data for two-group comparisons. Results: There was no substantial difference between the T2DM–CKD and T2DM–no CKD groups for tear film substance P concentration (4.4 (0.2–50.4) and 5.9 (0.2–47.2) ng/mL, respectively; p = 0.54). No difference was observed in tear film substance P concentration between the low-severity peripheral neuropathy and high-severity peripheral neuropathy groups (4.4 (0.2–50.4) and 3.3 (0.3–40.7) ng/mL, respectively; p = 0.80). Corneal nerve fiber length (9.8 ± 4.6 and 12.4 ± 3.8 mm/mm2, respectively; p = 0.04) and corneal nerve fiber density (14.7 ± 8.5 and 21.1 ± 7.0 no/mm2, respectively; p < 0.01) were reduced significantly in the T2DM–CKD group compared to the T2DM–no CKD group. There were significant differences in corneal nerve fiber density (21.0 ± 8.1 and 15.8 ± 7.7 no/mm2, respectively; p = 0.04) and corneal nerve fiber length (12.9 ± 4.2 and 9.7 ± 3.8 mm/mm2, respectively; p = 0.03) between the low- and high-severity peripheral neuropathy groups. Conclusion: In conclusion, no significant difference in tear film substance P concentration was observed between type 2 diabetes with and without CKD. Corneal nerve loss, however, was more significant in type 2 diabetes with chronic kidney disease compared to type 2 diabetes alone, indicating that corneal nerve morphological measures could serve greater utility as a tool to detect neuropathy and nephropathy-related corneal nerve changes.
- Published
- 2023
- Full Text
- View/download PDF
3. Corneal dendritic cells and the subbasal nerve plexus following neurotoxic treatment with oxaliplatin or paclitaxel
- Author
-
Jeremy Chung Bo Chiang, David Goldstein, Azadeh Tavakoli, Terry Trinh, Jacob Klisser, Craig R. Lewis, Michael Friedlander, Thomas J. Naduvilath, Kimberley Au, Susanna B. Park, Arun V. Krishnan, and Maria Markoulli
- Subjects
Medicine ,Science - Abstract
Abstract Immune cell infiltration has been implicated in neurotoxic chemotherapy for cancer treatment. However, our understanding of immune processes is still incomplete and current methods of observing immune cells are time consuming or invasive. Corneal dendritic cells are potent antigen-presenting cells and can be imaged with in-vivo corneal confocal microscopy. Corneal dendritic cell densities and nerve parameters in patients treated with neurotoxic chemotherapy were investigated. Patients treated for cancer with oxaliplatin (n = 39) or paclitaxel (n = 48), 3 to 24 months prior to assessment were recruited along with 40 healthy controls. Immature (ImDC), mature (MDC) and total dendritic cell densities (TotalDC), and corneal nerve parameters were analyzed from in-vivo corneal confocal microscopy images. ImDC was increased in the oxaliplatin group (Median, Md = 22.7 cells/mm2) compared to healthy controls (Md = 10.1 cells/mm2, p = 0.001), but not in the paclitaxel group (Md = 10.6 cells/mm2). ImDC was also associated with higher oxaliplatin cumulative dose (r = 0.33, p = 0.04) and treatment cycles (r = 0.40, p = 0.01). There was no significant difference in MDC between the three groups (p > 0.05). Corneal nerve parameters were reduced in both oxaliplatin and paclitaxel groups compared to healthy controls (p
- Published
- 2021
- Full Text
- View/download PDF
4. A cross-sectional study of ocular surface discomfort and corneal nerve dysfunction after paclitaxel treatment for cancer
- Author
-
Jeremy Chung Bo Chiang, David Goldstein, Terry Trinh, Kimberley Au, Susanna B. Park, Arun V. Krishnan, and Maria Markoulli
- Subjects
Medicine ,Science - Abstract
Abstract Ocular surface dysfunction is common in patients receiving anti-cancer drug treatment. The effects of paclitaxel, a neurotoxic chemotherapeutic drug, on ocular surface discomfort associated with dry eye disease was investigated. Patients with cancer who had completed paclitaxel treatment between 3 and 24 months prior to assessment (n = 29) and age- and sex-matched healthy control subjects (n = 29) were recruited and assessed with the Ocular Surface Disease Index (OSDI) to measure ocular surface discomfort. In-vivo corneal confocal microscopy was used to evaluate corneal nerve parameters in the right eye. Peripheral neurotoxicity was assessed using patient-reported outcomes and clinical grading scales. The paclitaxel group had significantly worse OSDI total scores compared with controls (Median, Md = 19.3 and Md = 0, p = 0.007, respectively). Corneal nerve fiber and inferior whorl lengths were reduced in the paclitaxel group compared with controls (14.2 ± 4.0 and 14.4 ± 4.0 mm/mm2 vs. 16.4 ± 4.0 and 16.9 ± 4.9 mm/mm2, respectively, p = 0.04). When analyzed by presence of peripheral neuropathy, paclitaxel-treated patients with neuropathy showed worse OSDI total scores compared to those without peripheral neuropathy post-treatment (p = 0.001) and healthy controls (p
- Published
- 2021
- Full Text
- View/download PDF
5. Review of referrals reveal the impact of referral content on the triage and management of ophthalmology wait lists
- Author
-
Angelica Ly, Barbara Zangerl, Michael Kalloniatis, Michael Yapp, Vincent Khou, Lindsay Moore, Maria Markoulli, and Michael Hennessy
- Subjects
Medicine - Published
- 2021
- Full Text
- View/download PDF
6. Current and Emerging Pharmacotherapeutic Interventions for the Treatment of Peripheral Nerve Disorders
- Author
-
Jeremy Chung Bo Chiang, Ria Arnold, Roshan Dhanapalaratnam, Maria Markoulli, and Arun V. Krishnan
- Subjects
cancer ,chemotherapy ,chronic kidney failure ,diabetes mellitus ,immune system diseases ,neuropathy ,Medicine ,Pharmacy and materia medica ,RS1-441 - Abstract
Peripheral nerve disorders are caused by a range of different aetiologies. The range of causes include metabolic conditions such as diabetes, obesity and chronic kidney disease. Diabetic neuropathy may be associated with severe weakness and the loss of sensation, leading to gangrene and amputation in advanced cases. Recent studies have indicated a high prevalence of neuropathy in patients with chronic kidney disease, also known as uraemic neuropathy. Immune-mediated neuropathies including Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy may cause significant physical disability. As survival rates continue to improve in cancer, the prevalence of treatment complications, such as chemotherapy-induced peripheral neuropathy, has also increased in treated patients and survivors. Notably, peripheral neuropathy associated with these conditions may be chronic and long-lasting, drastically affecting the quality of life of affected individuals, and leading to a large socioeconomic burden. This review article explores some of the major emerging clinical and experimental therapeutic agents that have been investigated for the treatment of peripheral neuropathy due to metabolic, toxic and immune aetiologies.
- Published
- 2022
- Full Text
- View/download PDF
7. U-Net Segmented Adjacent Angle Detection (USAAD) for Automatic Analysis of Corneal Nerve Structures
- Author
-
Philip Mehrgardt, Seid Miad Zandavi, Simon K. Poon, Juno Kim, Maria Markoulli, and Matloob Khushi
- Subjects
U-Net ,deep learning ,corneal nerve ,automatic analysis ,tortuosity ,Bibliography. Library science. Information resources - Abstract
Measurement of corneal nerve tortuosity is associated with dry eye disease, diabetic retinopathy, and a range of other conditions. However, clinicians measure tortuosity on very different grading scales that are inherently subjective. Using in vivo confocal microscopy, 253 images of corneal nerves were captured and manually labelled by two researchers with tortuosity measurements ranging on a scale from 0.1 to 1.0. Tortuosity was estimated computationally by extracting a binarised nerve structure utilising a previously published method. A novel U-Net segmented adjacent angle detection (USAAD) method was developed by training a U-Net with a series of back feeding processed images and nerve structure vectorizations. Angles between all vectors and segments were measured and used for training and predicting tortuosity measured by human labelling. Despite the disagreement among clinicians on tortuosity labelling measures, the optimised grading measurement was significantly correlated with our USAAD angle measurements. We identified the nerve interval lengths that optimised the correlation of tortuosity estimates with human grading. We also show the merit of our proposed method with respect to other baseline methods that provide a single estimate of tortuosity. The real benefit of USAAD in future will be to provide comprehensive structural information about variations in nerve orientation for potential use as a clinical measure of the presence of disease and its progression.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.